Biology subjects

Valkovic, A.

Publications and source records attributed to Valkovic, A..

4 recordsLinked to original sources

bioRxiv2025

A new genetically engineered transplant model of glioma recapitulates key phenotypes of low- and high-grade gliomas

Immune competent animal models are essential in preclinical glioma research. The ability to investigate tumor development with key tumor microenvironment components such as immune infiltration, stromal cells and extracellular matrix allows for the investigation of these complex tumors. However, the current range of syngeneic models of glioma possess intrinsic limitations which must be acknowledged when designing a preclinical study. To address this gap, we developed genetically engineered mouse cell line models (GEM-CLeMs) by introducing common glioma driver mutations into immortalized astrocytes. A high-grade glioma model was generated by combining Pten knockdown with RAS V12 overexpression, while a low-grade glioma model was produced through p53 knockdown with mutant IDH1R132H overexpression. The RAS/Pten GEM-CLeM tumors grew rapidly in vivo, displayed necrosis, multinucleated pleomorphisms, abundant vascularization, and showed strong enrichment for extracellular matrix remodelling and mesenchymal genes, features closely aligned with human glioblastoma. Importantly, the RAS/Pten GEM-CLeM tumors showed similar survival trends and immune infiltration patterns as a corresponding KrasG12D/PtencKO GEMM, but could be grown to larger sizes, facilitating better stromal and immune analyses. In contrast, the IDH1R132H/p53 GEM-CLeM formed slow-growing tumors with distinctive immune infiltration and vascular patterns, consistent with low-grade glioma phenotypes. Compared with the commonly used cell line GL261, the GEM-CLeM tumors had higher levels of stromal integration and immune suppression, making them a more faithful model of the glioma tumor microenvironment. This system enables rapid generation of transplantable glioma models with defined driver mutations in a low-mutational background, offering a flexible platform for dissecting glioma biology and evaluating immunotherapies. Importance of the studyWe have generated a set of customizable, modular Genetically Engineered Mouse Cell Line Models (GEM-CLeMs) of "high grade" and "low grade" glioma. They reliably form tumors when transplanted intracranially into immune-competent C57BL/6 mice, and they are cost- and time-effective at capturing the important characteristics of glioma, both mutant IDH1 low grade glioma and high grade glioblastoma. Critically these characteristics include the myeloid-rich immune suppressive tumor immune microenvironment, a key weakness of existing murine glioma cell lines like GL261. These GEM-CLeM models can be used in multiple ways. The cells are amenable to further manipulation, so therapeutic targets and drug mechanism of action can be assessed. The activity of candidate genes in tumour formation and phenotype can be determined. Most importantly the models can be used to develop effective immunotherapies, including strategies to target macrophage and myeloid cell immune suppression. Key pointsO_LICombinations of driver mutations were engineered into an immortalised mouse astrocyte. C_LIO_LIEngineered cells formed tumours on intracranial transplant into immune competent mice. C_LIO_LITumors had key histological and immune suppressive features of human glioma. C_LI

cancer biology↗

bioRxiv2025

Three-dimensional patient-derived models of glioblastoma retain intra-tumoral heterogeneity

The intra- and inter-tumoral heterogeneity of glioblastoma represents a significant therapeutic challenge, as well as difficulty in generating reliable models for in vitro studies. Historical 2D adherent cell lines do not recapitulate this complexity, whereas both patient-derived neurospheres (PDN) and organoids (PDO) demonstrate intra-tumoral heterogeneity. Here, we quantify the tumor cell composition from matched models established from the same primary tumor using a series of multi-omic interrogations. We find that both patient-derived models recapitulate the genomic, epigenomic and tumor cell heterogeneity of the primary tissue. Furthermore, single-nuclei RNA sequencing revealed a subset of organoids containing small numbers of non-malignant cells from neuron and immune cell lineages. Harnessing the intra-tumoral heterogeneity of PDN models, we reveal the impact of temozolomide chemotherapy on individual cell states, altering composition of tumors over time in response to treatment. Our data confirms that both patient-derived models recapitulate patient intra-tumoral heterogeneity providing a platform for tumor cell state refined therapeutic studies. Key PointsO_LIGeneration of matched patient-derived neurosphere and organoid models from resected GBM tissue C_LIO_LINeurosphere models exhibit greater proliferative signatures C_LIO_LIBoth patient-derived models recapitulate genomic and epigenomic features of the primary tissue C_LIO_LISingle-nuclei RNA sequencing reveals both models recapitulate intra-tumoral heterogeneity of the primary tissue C_LIO_LINeurosphere models enable interrogation of therapeutic responses in the context of heterogeneity C_LI Importance of studyPatient derived models can be powerful tools when they faithfully recapitulate the tumor tissue from which they are derived. In glioblastoma, patient derived neurospheres (PDN) and organoids (PDO) have both been used in studies, however the differences between these models and the recapitulation of patient heterogeneity remain to be fully characterized. To address this, we performed multi-omic profiling of PDN and PDO models generated from the same tumor tissue. We find that that across a range of data modalities, both model systems exhibit a high level of resemblance to tissue, and critically, maintain heterogeneity and tumor cell composition. The importance of modeling heterogeneity was demonstrated in PDN models, where temozolomide treatment specifically alters the abundance of MES-like and AC-like tumor cells. Our findings demonstrate that neurosphere and organoid models effectively preserve cellular heterogeneity, genomic alterations, methylation signatures and transcriptomic features, both highly suitable to model glioblastomas complex cellular landscape.

cancer biology↗

bioRxiv2024

An integrative spatial multi-omic workflow for unified analysis of tumor tissue

Combining molecular profiling with imaging techniques has advanced the field of spatial biology, offering new insights into complex biological processes. Focusing on diffuse IDH-mutated low-grade glioma, this study presents a workflow for Spatial Multi-omics Integration, SMINT, specifically combining spatial transcriptomics and spatial metabolomics. Our workflow incorporates both existing and custom-developed computational tools to enable cell segmentation and registration of spatial coordinates from both modalities to a common coordinate framework. During our investigation of cell segmentation strategies, we found that nuclei-only segmentation, while containing only 40% of segmented cell transcripts, enables accurate cell type annotation, but does not account for multinucleated cells. Our integrative workflow including cell-morphology segmentation identified distinct cellular neighborhoods at the infiltrating edge of gliomas, which were enriched in multinucleated and oligodendrocyte-lineage tumor cells, that may drive tumor invasion into the normal cortical layers of the brain. HighlightsO_LIAlignment and integrated analysis of spatial transcriptomic and metabolomic data C_LIO_LINuclei-only and cell-morphology segmentations are concordant for cell annotation C_LIO_LISpatially distinct regions are conserved in transcriptomic and metabolomic datasets C_LIO_LIMulti-omic exploration of glioma leading edge identifies novel biological features C_LI

bioinformatics↗

bioRxiv2023

Matrix selection for the visualization of small molecules and lipids in brain tumors using untargeted MALDI-TOF mass spectrometry imaging

Matrix-assisted laser desorption/ionization mass spectrometry imaging allows the study of metabolic activity in the tumor microenvironment of brain cancers. The detectable metabolites within these tumors are contingent upon the choice of matrix, deposition technique, and polarity setting. In this study, we compared the performance of three different matrices, two deposition techniques, and use of positive and negative polarity in two different brain cancer types and across two species. Optimal combinations were confirmed by comparative analysis of lipid and small molecule abundance using liquid chromatography-mass spectrometry and RNA-sequencing assessing differential metabolites between normal and tumor regions. Our findings indicate that the recrystallized cyano-4-hydroxycinnamic acid matrix in positive polarity offered superior performance for both detected metabolites and consistency with other techniques. Beyond these implications for brain cancer, our work establishes a workflow to identify optimal matrices for spatial metabolomics studies.

molecular biology↗